// App-Quantinova.ai

965 : Allogeneic Hematopoietic Stem Cell Transplantation Following Anti-CD19 BiTE Blinatumomab in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

Researchers

Presenter

  • Anthony Stein

Principal Investigators

  • Max S. Topp

  • Nicola Goekbuget

  • Tapan Maniar

  • Birgit Huber

  • Dirk Nagorsen

  • Ralf C. Bargou

  • Herve Dombret

  • Adele K. Fielding

  • Richard A. Larson

  • Alessandro Rambaldi

  • Gary Schiller

  • Gerhard Zugmaier

  • Catherine Jia

Medical Centers

  • City of Hope, Duarte, CA

  • Department of Medicine II, Goethe University, Frankfurt, Germany

  • Department of Hematology, University College London Medical School, Royal Free Campus, London, United Kingdom

  • The University of Chicago Medical Center, Chicago, IL

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Department of Hematology, Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy

  • Comprehensive Cancer Center Mainfranken, Universitaetsklinikum Wuerzburg, Wuerzburg, Germany

  • University of California, Los Angeles, Los Angeles, CA

  • University Paris, Hopital Saint-Louis, Paris, France

  • Medizinische Klinik und Poliklinik II, Universitatsklinikum Wurzburg, Wurzburg, Germany

Locations

  • Italy

  • Germany

  • United Kingdom

  • United States

  • France

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved